Form 4: Akero Therapeutics Chief Scientific Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, sold 537 shares of common stock on September 10, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On September 10, 2024, Timothy Rolph, the Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), sold 537 shares of the company's common stock.
- The sale was executed at a price of $26.18 per share.
- This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units, in accordance with Akero Therapeutics' 'sell-to-cover' policy.
- Following the transaction, Rolph directly owns 180,705 shares of Akero Therapeutics.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine transaction to cover tax obligations and doesn't indicate a positive or negative outlook for the company.
Industry Context
This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It doesn't necessarily reflect a change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 09/10/2024 | Date of stock sale transaction. |
| 09/13/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.